Business Wire

HEINEKEN Teams Up With Blue Yonder To Improve Demand Planning

15.5.2024 11:00:00 EEST | Business Wire | Press release

Share

HEINEKEN, the world’s most international brewer, confirms Blue Yonder as a vendor of trust to further transform its supply chain planning capability. The global brewer will implement Blue Yonder Cognitive Demand Planning, a next generation cloud-native, microservices-based SaaS solution, that utilizes artificial intelligence (AI) and machine learning (ML) to improve forecast accuracy and reduce bias by considering dynamic external and internal variables.

HEINEKEN has been implementing Blue Yonder solutions for multiple years unlocking value for its business, especially with the potential to improve forecast accuracy through ML demand forecasting solution. HEINEKEN has selected Blue Yonder, as one of the current major supply chain solution providers, to future proof its demand planning process and leverage AI/ML, autonomous scenario planning, planning process orchestration and solution extensibility.

“We want to continuously improve our supply chain processes and adopting Blue Yonder Cognitive Demand Planning is an important step in that ambition. Working together with Blue Yonder will support us in our ambition to become the best-connected brewer and foster functional excellence in demand planning, leading to improved customer experience. And with the right supply response it could generate a positive impact on our sustainability targets as well, for example by reduced write-offs and less goods movements,” said Corneel Hindriks, manager, Digital & Technology - Global Planning, HEINEKEN.

Once the Blue Yonder Cognitive Demand Planning solution is implemented, HEINEKEN expects to achieve the following benefits:

  • Make more informed, data-driven decisions: get all the real-world and business data HEINEKEN needs in a unified data cloud and integrate all planning processes to make better decisions – with speed and scale.
  • Manage complexity and boost accuracy: combine the best output from statistical forecasting and extensible ML to deliver higher forecast accuracy and reduce bias.
  • Respond faster: compress the planning cycle and empower planners to drive strategy and respond in the moment, not on a fixed schedule.
  • Create and deploy customized and extended solutions: build, test and confidently deploy customized and extended ML models, workflows, personalized user experiences, and business logic at production scale with minimal effort.

Consumer goods companies are currently encountering challenges due to fluctuations in demand caused by inflation, supply chain disruptions, evolving consumer habits, and a growing demand for more sustainable products and processes. These industry dynamics pose a significant challenge for conventional forecasting methods. Blue Yonder Cognitive Demand Planning solution, which sits on Microsoft Azure, addresses these challenges with a new generation of AI-based capabilities, transforming the way companies around the world collaborate, predict, plan and make decisions.

“We are proud to bring our contribution as supply chain management leaders in supporting HEINEKEN’s mission to become the best-connected brewer. Blue Yonder’s future-proof solution helps a brewer like HEINEKEN to adapt to new external dynamics and changing market conditions, ensuring their supply chains remain agile, sustainable and competitive. Thanks to Blue Yonder Cognitive Demand Planning, HEINEKEN can optimize its supply chain and ensure that customers can always enjoy their preferred beers and beyond all over the world,” said Terry Turner, President, Manufacturing, Blue Yonder.

Additional Resources:

About Heineken

HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 350 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 90,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, maltings, cider plants and other production facilities in more than 70 countries. The most recent information is available on the Company's website and follow us on LinkedIn, Twitter and Instagram. For press inquiry please contact pressoffice@heineken.com.

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential™ blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Blue Yonder Public Relations:
Marina Renneke, APR, Global Corporate Communications Sr. Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com

Rossella Benti, EMEA Corporate Communications Director
Tel: +39 335 7849149, rossella.benti@blueyonder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye